Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multi-centre, double-blind, randomised, parallel-group, placebo-controlled phase III study of the efficacy and safety of quetiapine fumarate sustained release (Seroquel SRTM) in combination with an antidepressant in the treatment of patients with major depressive disorder with inadequate response to an antidepressant treatment

Next Previous
X
Search
Trial Profile

A multi-centre, double-blind, randomised, parallel-group, placebo-controlled phase III study of the efficacy and safety of quetiapine fumarate sustained release (Seroquel SRTM) in combination with an antidepressant in the treatment of patients with major depressive disorder with inadequate response to an antidepressant treatment

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 29 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Quetiapine (Primary)
  • Indications Depression; Major depressive disorder
  • Focus Registrational; Therapeutic Use
  • Acronyms ONYX
  • Sponsors AstraZeneca

    • Most Recent Events

    • 22 May 2010 Results from a pooled analysis with the PEARL trial [see trial profile 24355] were presented at the 163rd Annual Meeting of the American Psychiatric Association.
    • 04 Dec 2009 The FDA approval of SEROQUEL for add-on treatment of Major Depressive Disorder was based on a supplemental new drug application (sNDA) comprising findings from this and another phase III trial (see trial profile 700024355).
    • 01 Apr 2009 Results published in the Journal of Clinical Psychiatry.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top